SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Vivimed Labs surges on receiving favourable outcome for its API manufacturing facility in Spain

21 Sep 2015 Evaluate

Vivimed Labs is currently trading at Rs. 297.00, up by 8.10 points or 2.80% from its previous closing of Rs. 288.90 on the BSE.

The scrip opened at Rs. 286.00 and has touched a high and low of Rs. 312.00 and Rs. 283.30 respectively. So far 59528 shares were traded on the counter.

The BSE group 'B ' stock of face value Rs. 10 has touched a 52 week high of Rs. 435.40 on 01-Dec-2014 and a 52 week low of Rs. 175.00 on 24-Jun-2015.

Last one week high and low of the scrip stood at Rs. 315.20 and Rs. 280.00 respectively. The current market cap of the company is Rs. 484.82 crore.

The promoters holding in the company stood at 36.99% while Institutions and Non-Institutions held 27.69% and 35.32% respectively.

Vivimed Labs, a niche specialty chemicals and pharmaceuticals company, has received a favourable outcome for its API manufacturing facility located in Lliga de Vail, Spain post its US Food and Drug Administration (USFDA) inspection. The audit was conducted during the second week of September and concluded on September 18, 2015.

On completion of the inspection the USFDA inspectors concluded that the facility, its systems and practices comply with USFDA requirements with no observations reported on the form 483.

The company during the last one year has had a satisfactory outcome on the regulatory compliance front with all four of its USFDA approved manufacturing plants including Sant Celoni, Spain (May 2015), Alathur, India (February 2015), Cuernavaca, Mexico (September 2014) and now Lliga de Vail, Spain.

Vivimed Labs is a listed company engaged in the business of manufacturing products (active ingredients, formulations, etc) for pharmaceutical, personal care and colour chemistry industry. VLL (Consolidated) has manufacturing facilities in India and Overseas.

 

 

Vivimed Labs Share Price

7.26 -0.38 (-4.97%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×